Clinical trials: Hyperplasia
Familial Adenomatous Polyposis Coli, FAP
Chemoprevention Trial in Familial Adenomatous Polyposis (FAP) Coli Using EPA
This purpose of this study is to investigate whether the number and size of rectal polyps can be reduced in patients with Familial Adenomatous Polyposis (FAP) by using a highly-purified form of a naturally occurring substance…
- Trial name
- NCT00510692
- Testing
- Eicosapentanoic Acid (EPA), Endoscopy, Biopsies taken
- Where
- United Kingdom
- Volunteers
- 58 people
- Sponsor
- S.L.A. Pharma AG
Benign Prostatic Hyperplasia
A Study of an Investigational Study Drug for Benign Prostatic Hyperplasia (0906-140)
The purpose of this trial is to determine the efficacy and safety of an investigational drug in patients with benign prostatic hyperplasia.
- Trial name
- NCT00127179
- Testing
- MK0906, finasteride / Duration of Treatment: 48 weeks
- Volunteers
- 600 people
- Sponsor
- Organon and Co
Benign Prostatic Hyperplasia, Prostatic Hyperplasia
Dutasteride 0.5mg For The Treatment Of Chinese Patients With Benign Prostatic Hyperplasia (BPH)
This randomized, double-blind, placebo-controlled, six-month parallel-group study assess efficacy and safety of dutasteride 0.5mg once daily in Chinese patients with Benign Prostatic Hyperplasia (BPH) , followed by a 12-month…
- Trial name
- NCT00527605
- Testing
- Dutasteride 0.5mg capsule
- Where
- 12 sites in China
- Volunteers
- 253 people
- Sponsor
- GlaxoSmithKline
Prostatic Hyperplasia
ALF-STONE: Alfuzosin in Uretheric Stones
The aim of the study is to assess the effect of Alfuzosin compared with placebo, for 7 days, on the outcome of patients with uretheric stones submitted to Extracorporeal Shock Wave Lithotripsy (ESWL), namely in the percentage of…
- Trial name
- NCT00454402
- Testing
- Alfuzosin
- Where
- Portugal
- Volunteers
- 220 people
- Sponsor
- Sanofi
Acute Urinary Retention
Alfuzosin for Treating Acute Urinary Retention
The primary objective of the study is to assess the efficacy of alfuzosin 10mg daily in the return to successful voiding after removal of the catheter following a first episode of acute urinary retention (AUR) in patients…
- Trial name
- NCT00336921
- Testing
- Alfuzosin
- Where
- China
- Volunteers
- 156 people
- Sponsor
- Sanofi
Hemodialysis Graft Dysfunction
Use of ABI-007 for the Prevention of Vascular Access Graft Failure in Patients Undergoing Hemodialysis
This study is designed to confirm the safety of the proposed dose and schedule of ABI-007 for hemodialysis patients with vascular access device failure, and to obtain preliminary data on the effectiveness of such treatment.
- Trial name
- NCT00249002
- Testing
- ABI-007
- Where
- 4 sites in United States
- Volunteers
- 9 people
- Sponsor
- Celgene
Benign Prostatic Hyperplasia
Safety and Feasibility of the XFLO Expander System (Mercury)
To demonstrate the safety and feasibility of the Mercury Expander system and procedure to treat patients with lower urinary tract symptoms (LUTS) secondary to urinary outflow obstruction from benign prostatic hyperplasia.
- Trial name
- EXPANDER-1 (NCT03758222)
- Testing
- XFLO Expander System
- Where
- 5 sites in Australia, Canada and 2 more
- Volunteers
- 45 people
- Sponsor
- MedeonBio, Inc.
Benign Prostatic Hyperplasia
Study of Tadalafil Once-a-Day for 12 Weeks in Japanese Men With Benign Prostatic Hyperplasia Followed by an Open-Label Extension
This study is a randomized, double-blind, placebo-controlled, parallel-design to compare the efficacy and safety of tadalafil once-a-day dosing versus placebo for 12 weeks followed by an open-label extension to evaluate the…
- Trial name
- NCT00783094
- Testing
- Tadalafil 2.5 mg, Tadalafil 5 mg
- Where
- 6 sites in Japan
- Volunteers
- 422 people
- Sponsor
- Eli Lilly and Company
Benign Prostatic Hyperplasia, Benign Prostatic Hyperplasia With Lower Urinary Tract Symptoms
A Phase III Clinical Study of H077 Sustained-Release Tablets Compared With Silodosin Capsules in the Treatment of Benign Prostatic Hyperplasia
This is a randomized, double-blind, controlled, non-inferiority multicenter Phase III clinical study to evaluate the efficacy and safety of H077 sustained-release tablets versus silodosin capsules in treating benign prostatic…
- Trial name
- NCT07146386
- Testing
- H077 sustained-release tablet, Silodosin capsules Control Group
- Where
- 66 sites in China
- Volunteers
- 728 people
- Sponsor
- Shanghai Huilun Pharmaceutical Co., Ltd.
Benign Prostate Hyperplasia
A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of HGP0412 and HIP1402 in Patients With BPH
The main objective of this study is to evaluate efficacy and safety of (Tamsulosin) HGP0412 and HIP1402 in patients with Benign Prostatic Hyperplasia
- Trial name
- NCT02390882
- Testing
- HGP0412 capsule, HIP1402 capsule
- Where
- South Korea
- Volunteers
- 494 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Benign Prostate Hyperplasia
Efficacy and Safety of Tamsulosin/Solifenacin Combination Therapy in Patients With Voiding Symptoms and Moderate to Severe Storage Symptoms Due to Benign Prostate Hyperplasia
Efficacy and Safety of Tamsulosin/Solifenacin Combination therapy in Patients with voiding symptoms and moderate to severe storage symptoms due to Benign Prostate Hyperplasia : a randomized, double blinded, parallel design…
- Trial name
- NCT02827578
- Testing
- Tamsulosin, Solifenacin
- Where
- South Korea
- Volunteers
- 588 people
- Sponsor
- IlDong Pharmaceutical Co Ltd
Prostatic Hyperplasia, Prostate
Study to Determine Safety and Effectiveness of Tadalafil on Prostate Related Sex Organ/Urinary Tract Problems
Study to look at safety and effectiveness of different doses of tadalafil on prostate related genital/urinary tract problems.
- Trial name
- PILUTS (NCT00547625)
- Testing
- tadalafil
- Where
- United States
- Volunteers
- 275 people
- Sponsor
- Eli Lilly and Company
Benign Prostatic Hyperplasia
A Study in Benign Prostatic Hyperplasia
The purpose of this trial is to evaluate the effect of tadalafil 5 milligrams (mg) daily for 8 weeks compared to placebo on prostatic blood perfusion in men with signs and symptoms of Benign Prostatic Hyperplasia (BPH), measured…
- Trial name
- NCT01152190
- Testing
- Tadalafil
- Where
- 5 sites in United States, Austria and 1 more
- Volunteers
- 97 people
- Sponsor
- Eli Lilly and Company
Benign Prostatic Hyperplasia
Clinical Trial To Evaluate the Efficacy and Safety of CKD-397 in Benign Prostatic Hyperplasia Patients
A Multicenter, Randomized, Double-blind, Active-controlled, Parallel group, Phase III Clinical Trial To Evaluate the Efficacy and Safety of CKD-397 in Benign Prostatic Hyperplasia Patients.
- Trial name
- NCT03246880
- Testing
- Tamsulosin 0.2mg, Tadalafil 5mg
- Where
- South Korea
- Volunteers
- 455 people
- Sponsor
- Chong Kun Dang Pharmaceutical
Mouth Diseases
Evaluation of Oral Potentially Malignant Disorders (OPMDs) with STRATICYTE™
The purpose of this study is to validate the ability of the STRATICYTE™ predictive model to predict the transformation of oral potentially malignant disorders (OPMDs) to oral squamous cell carcinoma (OSCC) in a retrospective…
- Trial name
- NCT05853783
- Testing
- STRATICYTE™ Test
- Where
- 5 sites in United States
- Volunteers
- 180 people
- Sponsor
- Proteocyte Diagnostics Inc.
Nocturia, Benign Prostatic Hypertrophy (BPH)
Dose Response Study of VA106483 in Males With Nocturia and Benign Prostatic Hypertrophy (BPH)
The purpose of this study is to establish the dose response relationship of VA106483 and nocturnal urine volumes in a population of elderly male subjects with Benign Prostatic Hypertrophy (BPH) who are likely to present with…
- Trial name
- NCT01330927
- Testing
- VA106483
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- Vantia Ltd
Urinary Calculi, Benign Prostatic Hyperplasia
Flexiva Pulse Registry
To obtain post-market safety and efficacy data for FlexivaTM Pulse High Power Single-Use Laser Fibers during lithotripsy and soft tissue procedure of holmium laser enucleation of the prostate (HoLEP).
- Trial name
- NCT05027971
- Testing
- Flexiva Pulse High Power Single-Use Laser Fibers
- Where
- 4 sites in United States
- Volunteers
- 201 people
- Sponsor
- Boston Scientific Corporation
Benign Prostatic Hyperplasia
Pharmacovigilance Study To Evaluate Safety Of AVODART In Subjects With Benign Prostate Hyperplasia
This study has 4 phases: screening phase (visit 1), treatment phase (visit 2 - 6 mths after treatment initiation), and end of treatment phase (visit 3 - end of year 1).
- Trial name
- NCT00593593
- Volunteers
- 1,000 people
- Sponsor
- GlaxoSmithKline
Benign Prostatic Hyperplasia
A Study of Tadalafil in Benign Prostatic Hyperplasia
The purpose of this study is to investigate the pharmacokinetics of tadalafil in Japanese and non-Japanese men with Benign Prostatic Hyperplasia (BPH). The safety of tadalafil will also be studied.
- Trial name
- NCT01183650
- Testing
- Tadalafil
- Where
- Germany
- Volunteers
- 24 people
- Sponsor
- Eli Lilly and Company
Bladder Outlet Obstruction
Bladder Outlet Obstruction Observation Using Dynamic Urine Vibration "Holter"
Current gold standard of bladder outlet diagnosis is pressure flow study. This study is invasive time consuming and requires expensive and complex set-up.
- Trial name
- NCT01779349
- Testing
- Dynamic Urine Vibration "Holter"
- Where
- 2 sites in Israel
- Volunteers
- 45 people
- Sponsor
- P. Square Medical Ltd